Lay Summary: Multiple sclerosis (MS) does not affect everyone in the same way. Men and women experience different symptoms, disease progression, and treatment responses. Yet, most MS care option research does not consider these differences. Our team wanted to find out how current studies on MS care options consider the unique needs of men living with MS. We reviewed over 14,000 scientific articles. We found only 6 studies that looked at how care options affected the health of men, identified as sex or gender. Care options included sex hormone therapy, medication, and group therapy. Sex hormone therapy, specifically testosterone, slowed brain shrinkage in men with progressive MS. Androgen-modifying therapies showed increased disease activity in older men with relapsing remitting MS. Taffodil, an oral medicine, improved sexual function satisfaction. Disease-modifying therapies did not have a negative impact on fertility. Finally, completing a support group therapy increased self-satisfaction and promoted physical health. These findings should be reviewed with caution. There were a few studies done with a small number of participants. It is encouraging that, though there are few studies on care options for men with MS, positive results were seen. Our findings point to a significant gap in current knowledge. Without studying men-specific care options, we miss the chance to improve their health through more tailored care. Future MS research should place a focus on outcomes of care options specific to men. This can be done by changing how studies recruit, design, and analyze their data. This means researchers, funders, clinicians, and men living with MS must work together. By sharing our work, we hope to inspire more inclusive research that recognizes the differences between men and women living with MS.